Sotevtamab

Names

[ Name ]:
Sotevtamab

Biological Activity

[Description]:

Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research[1][2][3].

[Related Catalog]:

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

[In Vitro]

Sotevtamab 抑制 PANC-1 胰腺癌细胞的侵袭[3]。

[In Vivo]

Sotevtamab (10 and 50 mg/kg, i.v.) is well tolerated and shows no signs of toxicity in monkeys[3].

[References]

[1]. Gilles Tremblay, et al. Abstract 1467: AB-16B5, a therapeutic monoclonal antibody against human clusterin that blocks the epithelial-to-mesenchymal transition. Cancer Res 15 April 2010; 70 (8_Supplement): 1467.

[2]. Cristiano Ferrario, et al. Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies. Cancer Res 1 July 2017; 77 (13_Supplement): CT098.

[3]. Gilles B. et al. Pre-clinical evaluation of AB-16B5, a monoclonal antibody specific for tumor-associated sCLU, demonstrates therapeutic potential as an inhibitor of EMT in prostate, pancreatic and lung cancer. Cancer Res 15 April 2011; 71 (8_Supplement): LB–33.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.